Qianqian Yuan1, Gaosong Wu2, Shu-Yuan Xiao3,4, Yukun He1, Kun Wang5, Dan Zhang5. 1. Department of Thyroid and Breast Surgery, Zhongnan Hospital of Wuhan University, 169 Donghu Road, Wuhan, 430071, Hubei, People's Republic of China. 2. Department of Thyroid and Breast Surgery, Zhongnan Hospital of Wuhan University, 169 Donghu Road, Wuhan, 430071, Hubei, People's Republic of China. wugaosongtj@163.com. 3. Wuhan University Center for Pathology and Molecular Diagnostics, 169 Donghu Road, Wuhan, 430071, Hubei, People's Republic of China. 4. Department of Pathology, University of Chicago, Chicago, IL, 60637, USA. 5. Department of Thyroid and Breast Surgery, Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan, 430030, Hubei, People's Republic of China.
Abstract
BACKGROUND: False-negative rate (FNR) of sentinel lymph node dissection (SLND) has not been eliminated. The study was conducted to optimize the surgical resection of axilla in patients with negative sentinel lymph node (SLN) for the purpose of eradicating false-negative (FN) events of SLND. METHODS: A total of 312 clinically node-negative patients without neoadjuvant therapy underwent SLND with indocyanine green (ICG), methylene blue and the combination of ICG and methylene blue. Axillary dissection was performed subsequently regardless of the status of SLN. Lymph nodes were sent for pathological examination separately by serial resection every 0.5 cm away from marginally visualized SLNs. RESULTS: SLND was successfully conducted in 98.1% (306/312) of patients using methylene blue, ICG, and its combination. Further examination revealed 97 true-positive, 189 true-negative, and 13 FN results. The overall FNR was 11.8% (13/110). A horizontal line 1.5 cm away from the superior vSLN and a vertical line 1.5 cm away from the medial vSLN formed a zone of lower outer quadrant (LOQ) in axilla. Surgical resection of LOQ 'en bloc' showed a FNR of zero. CONCLUSIONS: The surgical management of axilla may benefit negative SLN patients with potential nodal involvement, reducing the FNR of SLND to zero. TRIAL REGISTRATION NUMBER AND AGENCY: This study was registered with the Chinese Clinical Trial Registry (ChiCTR1800014247).
BACKGROUND: False-negative rate (FNR) of sentinel lymph node dissection (SLND) has not been eliminated. The study was conducted to optimize the surgical resection of axilla in patients with negative sentinel lymph node (SLN) for the purpose of eradicating false-negative (FN) events of SLND. METHODS: A total of 312 clinically node-negative patients without neoadjuvant therapy underwent SLND with indocyanine green (ICG), methylene blue and the combination of ICG and methylene blue. Axillary dissection was performed subsequently regardless of the status of SLN. Lymph nodes were sent for pathological examination separately by serial resection every 0.5 cm away from marginally visualized SLNs. RESULTS: SLND was successfully conducted in 98.1% (306/312) of patients using methylene blue, ICG, and its combination. Further examination revealed 97 true-positive, 189 true-negative, and 13 FN results. The overall FNR was 11.8% (13/110). A horizontal line 1.5 cm away from the superior vSLN and a vertical line 1.5 cm away from the medial vSLN formed a zone of lower outer quadrant (LOQ) in axilla. Surgical resection of LOQ 'en bloc' showed a FNR of zero. CONCLUSIONS: The surgical management of axilla may benefit negative SLN patients with potential nodal involvement, reducing the FNR of SLND to zero. TRIAL REGISTRATION NUMBER AND AGENCY: This study was registered with the Chinese Clinical Trial Registry (ChiCTR1800014247).
Authors: Judy C Boughey; Vera J Suman; Elizabeth A Mittendorf; Gretchen M Ahrendt; Lee G Wilke; Bret Taback; A Marilyn Leitch; Teresa S Flippo-Morton; Henry M Kuerer; Monet Bowling; Kelly K Hunt Journal: Ann Surg Date: 2015-03 Impact factor: 12.969
Authors: M Brown; F P Assen; A Leithner; J Abe; H Schachner; G Asfour; Z Bago-Horvath; J V Stein; P Uhrin; M Sixt; D Kerjaschki Journal: Science Date: 2018-03-23 Impact factor: 47.728
Authors: Ted A James; Alex R Coffman; Anees B Chagpar; Judy C Boughey; V Suzanne Klimberg; Monica Morrow; Armando E Giuliano; Seth P Harlow Journal: Ann Surg Oncol Date: 2016-07-21 Impact factor: 5.344
Authors: David N Krag; Stewart J Anderson; Thomas B Julian; Ann M Brown; Seth P Harlow; Takamaru Ashikaga; Donald L Weaver; Barbara J Miller; Lynne M Jalovec; Thomas G Frazier; R Dirk Noyes; André Robidoux; Hugh M C Scarth; Denise M Mammolito; David R McCready; Eleftherios P Mamounas; Joseph P Costantino; Norman Wolmark Journal: Lancet Oncol Date: 2007-10 Impact factor: 41.316
Authors: Gary H Lyman; Mark R Somerfield; Linda D Bosserman; Cheryl L Perkins; Donald L Weaver; Armando E Giuliano Journal: J Clin Oncol Date: 2016-12-12 Impact factor: 44.544
Authors: Joost R van der Vorst; Boudewijn E Schaafsma; Floris P R Verbeek; Merlijn Hutteman; J Sven D Mieog; Clemens W G M Lowik; Gerrit-Jan Liefers; John V Frangioni; Cornelis J H van de Velde; Alexander L Vahrmeijer Journal: Ann Surg Oncol Date: 2012-07-03 Impact factor: 5.344